At Novatend, we are committed to advancing tissue engineering and biomaterial solutions to empower healthcare professionals and improve patient outcomes.
The team at Novatend are a mix of human tissue engineers, scientists, medical device representatives and business managers. We built Nova with the idea of delivering quality products at a reduced rate to ease the burden on patients while giving our surgeons devices that have a reliable and predictable clinical outcome. The result has been the regulatory approval and reimbursement of 15 products to date. We are growing quickly and look forward to all the hard but rewarding work that comes with it. The letters of thanks from patients and feedback from the surgeons alone make it worth it.
2022
Launched NovaMEM, a bioresorbable membrane for bone regeneration.
2024
Launched NovaGROW and began building client base after product launch
JUL
Developed NovaDBMX for the market based on customer demand and expanded clients base
APR
Founded with a mission to advance tissue engineering and regenerative medicine solutions.
2023
SAHPRA Accreditation to sell devices in the Republic of South Africa
MAR
55 Private Practices and 4 Day-hospitals regularly use the Nova line of products
2025
Launch of NovaDBM, NovatendX and our orthopaedics division. Market Expansion